Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist

British Journal of Clinical Pharmacology

Volumn 79, Issue 5, 2015, Pages 831-837

  Li, Chi Chung ^a   Vermeersch, Steve ^b   Denney, William S ^a,c,d   Kennedy, William P ^a,c,d   Palcza, John ^a   Gipson, Adrianna ^a   Han, Tae H ^a,c,d   Blanchard, Rebecca ^a   De Lepeleire, Inge ^a   Depré, Marleen ^b   Murphy, M Gail ^a   Van Dyck, Kristien ^a   De Hoon, Jan N ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c MSD Europe ^*  (United States)

^d South San Francisco ^*  (United States)

Author keywords

capsaicin; CGRP; human; MK 3207; vasodilatation

Indexed keywords

BIOLOGICAL MARKER; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CAPSAICIN; MK 2295; MK 3207; PLACEBO; TELCAGEPANT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; 2-(8-(3,5-DIFLUOROPHENYL)-10-OXO-6,9-DIAZASPIRO(4.5)DEC-9-YL)-N-(2'-OXO-1,1',2',3-TETRAHYDROSPIRO(INDENE-2,3'-PYRROLO(2,3-B)PYRIDIN)-5-YL)ACETAMIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; FUSED HETEROCYCLIC RINGS; SPIRO COMPOUND; TRPV1 PROTEIN, HUMAN; VANILLOID RECEPTOR;

ADULT; ANALGESIC ACTIVITY; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EC50; EC90; FIRST PASS EFFECT; HUMAN; HUMAN EXPERIMENT; LASER DOPPLER FLOWMETRY; MALE; MIGRAINE; NORMAL HUMAN; PERIPHERAL NERVE; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NERVE; SINGLE DRUG DOSE; SKIN BLOOD FLOW; SKIN BLOOD VESSEL; TIME TO MAXIMUM PLASMA CONCENTRATION; VASODILATATION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; PREDICTIVE VALUE; SKIN; VASCULARIZATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CAPSAICIN; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HEALTHY VOLUNTEERS; HUMANS; MALE; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SKIN; SPIRO COMPOUNDS; TRPV CATION CHANNELS; VASODILATION; YOUNG ADULT;

EID: 84928342643     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12547     Document Type: Article

References (25)

1. Raddant AC, Russo AF,. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med 2011; 13: e36.
2. Goadsby PJ, Sprenger T,. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol 2010; 9: 285-298.
3. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM, BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350: 1104-1110.
4. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK,. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008; 372: 2115-2123.
5. Papademetriou V,. Cardiovascular risk assessment and triptans. Headache 2004; 44 (Suppl. 1): S31-39.
6. Chan KY, Vermeersch S, de Hoon J, Villalõn CM, Maassenvandenbrink A,. Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects. Pharmacol Ther 2011; 129: 332-351.
7. Salvatore CA, Hershey JC, Corcoran HA, Fay JF, Johnston VK, Moore EL, Mosser SD, Burgey CS, Paone DV, Shaw AW, Graham SL, Vacca JP, Williams TM, Koblan KS, Kane SA,. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 2008; 324: 416-421.
8. Salvatore CA, Moore EL, Calamari A, Cook JJ, Michener MS, O'Malley S, Miller PJ, Sur C, Williams DL Jr, Zeng Z, Danziger A, Lynch JJ, Regan CP, Fay JF, Tang YS, Li CC, Pudvah NT, White RB, Bell IM, Gallicchio SN, Graham SL, Selnick HG, Vacca JP, Kane SA,. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther 2010; 333: 152-160.
9. Van der Schueren BJ, de Hoon JN, Vanmolkot FH, Van Hecken A, Depre M, Kane SA, De Lepeleire I, Sinclair SR,. Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging. Br J Clin Pharmacol 2007; 64: 580-590.
10. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D,. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389: 816-824.
11. Van der Schueren BJ, Rogiers A, Vanmolkot FH, Van Hecken A, Depré M, Kane SA, De Lepeleire I, Sinclair SR, de Hoon JN,. Calcitonin gene-related peptide 8-37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human in vivo pharmacodynamic model. J Pharmacol Exp Ther 2008; 325: 248-255.
12. Sinclair SR, Kane SA, Van der Schueren BJ, Xiao A, Willson KJ, Boyle J, de Lepeleire I, Xu Y, Hickey L, Denney WS, Li CC, Palcza J, Vanmolkot FH, Depré M, Van Hecken A, Murphy MG, Ho TW, de Hoon JN,. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). Br J Clin Pharmacol 2010; 69: 15-22.
13. Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R, Taraborelli D, Fan X, Assaid C, Lines C, Ho TW,. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 2011; 31: 712-722.
14. Vermeersch S, Van Hecken A, Abu-Raddad E, Benschop R, Montieth D, Scherer J, Grayzel D, de Hoon J, Collins E,. Translational pharmacodynamics of CGRP monoclonal antibody LY2951742 in capsaicin-induced dermal blood flow model. Cephalagia 2013; 33 (Suppl. 8): 249-250.
15. Fullerton A, Stücker M, Wilhelm KP, Wårdell K, Anderson C, Fischer T, Nilsson GE, Serup J, European Society of Contact Dermatitis Standardization Group. Guidelines for visualization of cutaneous blood flow by laser Doppler perfusion imaging. A report from the Standardization Group of the European Society of Contact Dermatitis based upon the HIRELADO European community project. Contact Dermat. 2002; 46: 129-140.
16. Denney WS, Hang Y, Dockendorf MF, Li C-C, Eid SR, Valesky R, Laethem T, Van Hoydonck P, De Lepeleire I, de Hoon JNJM, Crutchlow M, Blanchard R,. Modeling and simulation for determination of the therapeutic window of MK-2295: a TRPV1 antagonist. Presented at: Annual Meeting of the Population Approach Group in Europe (PAGE) 18; June 23-26, 2009; St. Petersburg, Russia. Abstract 1507. Available at http://www.page-meeting.org/?abstract=1507 (last accessed 2 October 2009).
17. Goadsby PJ, Edvinsson L, Ekman R,. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988; 23: 193-196.
18. Ho TW, Edvinsson L, Goadsby PJ,. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010; 6: 573-582.
19. Durham PL,. Calcitonin gene-related peptide (CGRP) and migraine. Headache 2006; 46 (Suppl. 1): S3-8.
20. Goadsby PJ, Edvinsson L,. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48-56.
21. Tfelt-Hansen P, Olesen J,. Possible site of action of CGRP antagonists in migraine. Cephalalgia 2011; 31: 748-750.
22. Vermeersch SGG, de Hoon J, De Saint-Hubert B, Derdelinckx I, Serdons K, Bormans G, Reynders T, Declercq R, De Lepeleire I, Kennedy W, Blanchard R, Marcantonio E, Hargreaves R, Li CC, Sanabria S, Hostetler E, Joshi A, Evelhoch J, Van Laere K,. PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act centrally to achieve clinical efficacy. J Headache Pain, Abstract Book of The European Headache and Migraine Trust International Congress 2013; 1 (Suppl. 1): P224. Available at http://www.thejournalofheadacheandpain.com/content/14/S1/P224.
23. Hostetler ED, Joshi AD, Sanabria-Bohõrquez S, Fan H, Zeng Z, Purcell M, Gantert L, Riffel K, Williams M, O'Malley S, Miller P, Selnick HG, Gallicchio SN, Bell IM, Salvatore CA, Kane SA, Li CC, Hargreaves RJ, de Groot T, Bormans G, Van Hecken A, Derdelinckx I, de Hoon J, Reynders T, Declercq R, De Lepeleire I, Kennedy WP, Blanchard R, Marcantonio EE, Sur C, Cook JJ, Van Laere K, Evelhoch JL,. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J Pharmacol Exp Ther 2013; 347: 478-486.
24. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS,. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 2014; 13: 885-892.
25. Reuter U,. Anti-CGRP antibodies: a new approach to migraine prevention. Lancet Neurol 2014; 13: 857-859.